Starlight Cardiovascular key facts
- Developer of a medical device intended to treat babies born with congenital heart disease.
- It has raised $9.5M; the latest was Early Stage VC in Aug 2024.
- Notable investors include Impact Assets, MedTech Innovator, National Institutes of Health, Catalytic Impact Foundation, Bird B. — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch Starlight Cardiovascular: the Monday email on marks, rounds and moves
Starlight Cardiovascular funding rounds
No funding rounds for Starlight Cardiovascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Starlight Cardiovascular investors
10 investors are on record for Starlight Cardiovascular, including Impact Assets, MedTech Innovator, National Institutes of Health and Catalytic Impact Foundation.
About Starlight Cardiovascular
Developer of a medical device intended to treat babies born with congenital heart disease. The company's devices are regenerative, infection resistant and have applications in cardiovascular patches, enabling healthcare professionals to improve the clinical outcomes of substitute conduit arteries in infants and children and reduce the risk of repetitive surgeries.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 8
- Website
- starlightcardio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Starlight Cardiovascular doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.